Ukraine

Bringing AI and digital healthtech innovation to patients works most efficiently via a three-way partnership in which clinicians and cloud services have equal weighting with a powerhouse innovator, Royal Philips told In Vivo during ECR 2025.

Tariffs, international cooperation, and war: the off-patent industry is not immune to the political issues raging across the globe. Medicines for Europe’s Adrian van den Hoven and Beata Stepniewska spoke with Generics Bulletin about what these developments mean for the sector.

Generics Bulletin reviews the latest regulatory developments across the world.

Krka has maintained strong growth in the past nine months despite ongoing questions surrounding its significant presence in Russia and foreign currency risks linked to the rouble.

Days after Gilead’s signing of voluntary licensing with six generic manufacturers for its HIV drug Sunleca, ViiV announced its commitment to ramping up Apretude’s supply to countries in need.

ProBiotix Health has announced two commercial partnerships for the distribution of its probiotic ingredients, with Deutsch-Pharm in Ukraine and Eifron in Greece respectively.

Seven “priority steps” to support Ukraine’s EU accession ambitions have been recommended to the European Commission in an open letter from Medicines for Europe, in conjunction with Ukraine’s European Business Association.

In the second part of a three-part interview with Generics Bulletin, Medicines for Europe director general Adrian van den Hoven discusses the rise in prominence of biosimilars in Europe, reflects on off-patent industry efforts to deal with crises such as the COVID-19 pandemic and the war in Ukraine, and highlights achievements such as the SPC manufacturing waiver.

Generics industry trade group Medicines for Europe has met with Ukrainian government officials to discuss how to plan for any future integration process.

Medicines for Europe has signed a memorandum of understanding with Ukraine’s European Business Association that aims to accelerate the country’s integration into the EU pharmaceutical market.